STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2143 by analyst upside · 2026-06-27
MASS
908 Devices Inc.
Healthcare · Market Cap $332M · P/E 0x
ANALYST PRICE TARGET
+25.3%
implied upside to consensus target
Current Price $8.78
Consensus Target $11.0
Bull Target $12.0
Bear Target $10.0
Analysts Covering 2
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $5.03
52-Week High $9.34
YTD Return +72.5%
FUNDAMENTALS
Market Cap $332M
P/E Ratio (TTM) N/A
Forward P/E -30.6x
EPS (TTM) $-0.97
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $58M
Profit Margin -62.4%
52-WEEK RANGE
52-Week Low $5.03
52-Week High $9.34
Current Price $8.78
Bear Target $10.0
Bull Target $12.0
● Now $8.78 ● Target $11.0
TRADING DATA
Avg Volume 279K
YTD Return +72.5%
Analyst Count 2
Consensus Buy
Upside to Target +25.3%
Last Updated 2026-06-27

ANALYST SUMMARY

908 Devices Inc. (MASS) is currently trading at $8.78 with a Wall Street consensus price target of $11.0, implying potential upside of 25.3% over the next 12 months. 2 analysts currently cover MASS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $10.0.

MASS operates in the Healthcare sector with a market capitalisation of $332M. The stock is up 72.5% year-to-date and is currently trading near the upper end of its 52-week range of $5.03 – $9.34.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MASS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↑ Upgrade
Market Perform → Outperform 2025-08-05 29% win rate (7 calls)
Stephens & Co. reit
Overweight → Overweight 2025-01-15 Building track record
Stifel — Reiterated
Buy → Buy 2024-11-13 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2024-11-13 29% win rate (7 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2024-10-17 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →